The report analyzes and forecasts the orphan drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of orphan drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major orphan drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of orphan drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of orphan drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global orphan drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the orphan drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of orphan drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Company Profiling
Amgen Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Novo Nordisk A/S, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc. are some of the topnotch players of this market. The leading companies account a major share of the market, making it very difficult for new players to enter the market.
For the purpose of this study, the market has been segmented as follows:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Section 2 Assumptions and Research Methodology
Section 3 Executive Summary
Section 4 Market Overview
4.1. Introduction
4.1.1 Product Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Rising prevalence of rare diseases
4.3.1.2. R&D Grants
4.3.1.3. Orphan Drugs provide high return on investments
4.3.1.4. First-mover advantage
4.3.1.5. Focus on awareness programs
4.3.1.6. Tax credits and fee waivers
4.3.2. Restraints
4.3.2.1. High cost of treatment
4.3.2.2. Dearth of trained medical professionals
4.3.2.3. Non-availability of approved drugs worldwide
4.3.2.4. Difficulty in recruiting for clinical trials
4.3.3. Opportunities
4.3.3.1. Unmet clinical needs
4.3.3.2. Strategic mergers and acquisitions
4.3.3.3. Repurposing of drugs
4.3.4. Trends
4.5. Global Orphan Drugs Market Analysis and Forecasts, 2017–2026
4.6. Market Outlook
4.7. Porter's Five Forces Analysis
4.8. Orphan Drug Manufacturing Companies – Acquisitions Timeline
4.9. Orphan Drugs Market- SWOT Analysis
4.10. Regulatory Scenario
4.11. Comparative Analysis of orphan drug policies
4.12. Rare Diseases Prevalence
4.13. Pricing – Orphan Drugs
4.14. Orphan Drugs – Price Volume Analysis
4.15. Major Conferences
4.16. Major selling Orphan drugs
4.17. Orphan Drugs – Drug Exclusivity
4.18. Clinical Trial Analysis
Section 5 Global Orphan Drugs Market Analysis and Forecasts, By Disease Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast By Disease Type, 2017–2026
5.3.1. Oncology
5.3.2. Gastrointestinal
5.3.3. Pulmonary
5.3.4. Neurology
5.3.5. Hematology
5.3.6. Cardiovascular
5.3.7. Metabolic Disorders
5.3.8. Endocrinology
5.3.9. Infectious Diseases
5.3.10. Others
5.4. Market Attractiveness By Disease Type
Section 6 Global Orphan Drugs Market Analysis and Forecasts, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2017–2026
6.3.1. Biologic
6.3.2. Non-biologic
6.4. Market Attractiveness By Product Type
Section 7 Global Orphan Drugs Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Distribution Channel, 2017–2026
7.3.1. Hospital Pharmacies
7.3.2. Specialty Pharmacies
7.3.3. Retail Pharmacies
7.3.4. Others
7.4. Market Attractiveness By Distribution Channel
Section 8 Global Orphan Drugs Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Rest of the World
8.3. Market Attractiveness by Region
Section 9 North America Orphan Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast By Country, 2017-2026
9.3.1. U.S.
9.3.2. Canada
9.4. Market Value Forecast By Disease Type, 2017–2026
9.4.1. Oncology
9.4.2. Gastrointestinal
9.4.3. Pulmonary
9.4.4. Neurology
9.4.5. Hematology
9.4.6. Cardiovascular
9.4.7. Metabolic Disorders
9.4.8. Endocrinology
9.4.9. Infectious Diseases
9.4.10. Others
9.5. Market Value Forecast By Product Type, 2017–2026
9.5.1. Biologic
9.5.2. Non-biologic
9.6. Market Value Forecast By Distribution Channel, 2017–2026
9.6.1. Hospital Pharmacies
9.6.2. Specialty Pharmacies
9.6.3. Retail Pharmacies
9.6.4. Others
9.7. Market Attractiveness Analysis
9.7.1. By Country
9.7.2. By Disease Type
9.7.3. By Product Type
9.7.4. By Distribution Channel
Section 10 Europe Orphan Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast By Country, 2017-2026
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Market Value Forecast By Disease Type, 2017–2026
10.4.1. Oncology
10.4.2. Gastrointestinal
10.4.3. Pulmonary
10.4.4. Neurology
10.4.5. Hematology
10.4.6. Cardiovascular
10.4.7. Metabolic Disorders
10.4.8. Endocrinology
10.4.9. Infectious Diseases
10.4.10. Others
10.5. Market Value Forecast By Product Type, 2017–2026
10.5.1. Biologic
10.5.2. Non-biologic
10.6. Market Value Forecast By Distribution Channel, 2017–2026
10.6.1. Hospital Pharmacies
10.6.2. Specialty Pharmacies
10.6.3. Retail Pharmacies
10.6.4. Others
10.7. Market Attractiveness Analysis
10.7.1. By Country
10.7.2. By Disease Type
10.7.3. By Product Type
10.7.4. By Distribution Channel
Section 11 Rest of the World Orphan Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast By Country, 2017-2026
11.3.1. Japan
11.3.2. Australia
11.3.3. China
11.3.4. Brazil
11.3.5. South Korea
11.3.6. Others
11.4. Market Value Forecast By Disease Type, 2017–2026
11.4.1. Oncology
11.4.2. Gastrointestinal
11.4.3. Pulmonary
11.4.4. Neurology
11.4.5. Hematology
11.4.6. Cardiovascular
11.4.7. Metabolic Disorders
11.4.8. Endocrinology
11.4.9. Infectious Diseases
11.4.10. Others
11.5. Market Value Forecast By Product Type, 2017–2026
11.5.1. Biologic
11.5.2. Non-biologic
11.6. Market Value Forecast By Distribution Channel, 2017–2026
11.6.1. Hospital Pharmacies
11.6.2. Specialty Pharmacies
11.6.3. Retail Pharmacies
11.6.4. Others
11.7. Market Attractiveness Analysis
11.7.1. By Country
11.7.2. By Disease Type
11.7.3. By Product Type
11.7.4. By Distribution Channel
Section 12 Country Snippets
Section 13 Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of companies)
13.2. Market Share Analysis By Company, 2016
13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.3.1. Novartis AG
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Business Overview
13.3.1.3. Product Portfolio
13.3.1.4. Financial Overview
13.3.1.5. SWOT Analysis
13.3.1.6. Strategic overview
13.3.2. Bristol-Myers Squibb Company
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Business Overview
13.3.2.3. Product Portfolio
13.3.2.4. Financial Overview
13.3.2.5. SWOT Analysis
13.3.2.6. Strategic overview
13.3.3. Celgene Corporation
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Business Overview
13.3.3.3. Product Portfolio
13.3.3.4. Financial Overview
13.3.3.5. SWOT Analysis
13.3.3.6. Strategic overview
13.3.4. F. Hoffmann-La Roche Ltd.
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Business Overview
13.3.4.3. Product Portfolio
13.3.4.4. Financial Overview
13.3.4.5. SWOT Analysis
13.3.4.6. Strategic overview
13.3.5. Pfizer, Inc.
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Business Overview
13.3.5.3. Product Portfolio
13.3.5.4. Financial Overview
13.3.5.5. SWOT Analysis
13.3.5.6. Strategic overview
13.3.6. Sanofi S.A.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Business Overview
13.3.6.3. Product Portfolio
13.3.6.4. Financial Overview
13.3.6.5. SWOT Analysis
13.3.6.6. Strategic overview
13.3.7. Alexion Pharmaceuticals, Inc.
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Business Overview
13.3.7.3. Product Portfolio
13.3.7.4. Financial Overview
13.3.7.5. SWOT Analysis
13.3.7.6. Strategic overview
13.3.8. Eli Lilly and Company
13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.8.2. Business Overview
13.3.8.3. Product Portfolio
13.3.8.4. Financial Overview
13.3.8.5. SWOT Analysis
13.3.8.6. Strategic overview
13.3.9. Novo Nordisk A/S
13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.9.2. Business Overview
13.3.9.3. Product Portfolio
13.3.9.4. Financial Overview
13.3.9.5. SWOT Analysis
13.3.9.6. Strategic overview
13.3.10. AstraZeneca plc
13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.10.2. Business Overview
13.3.10.3. Product Portfolio
13.3.10.4. Financial Overview
13.3.10.5. SWOT Analysis
13.3.10.6. Strategic overview
13.3.11. Eisai Co., Ltd.
13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.11.2. Business Overview
13.3.11.3. Product Portfolio
13.3.11.4. Financial Overview
13.3.11.5. SWOT Analysis
13.3.11.6. Strategic overview
13.3.12. Daiichi Sankyo Company Limited
13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.12.2. Business Overview
13.3.12.3. Product Portfolio
13.3.12.4. Financial Overview
13.3.12.5. SWOT Analysis
13.3.12.6. Strategic overview
13.3.13. Bayer AG
13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.13.2. Business Overview
13.3.13.3. Product Portfolio
13.3.13.4. Financial Overview
13.3.13.5. SWOT Analysis
13.3.13.6. Strategic overview
13.3.14. GlaxoSmithKline plc
13.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.14.2. Business Overview
13.3.14.3. Product Portfolio
13.3.14.4. Financial Overview
13.3.14.5. SWOT Analysis
13.3.14.6. Strategic overview
13.3.15. Merck & Co., Inc.
13.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.15.2. Business Overview
13.3.15.3. Product Portfolio
13.3.15.4. Financial Overview
13.3.15.5. SWOT Analysis
13.3.15.6. Strategic overview
13.3.16. Johnson & Johnson
13.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.16.2. Business Overview
13.3.16.3. Product Portfolio
13.3.16.4. Financial Overview
13.3.16.5. SWOT Analysis
13.3.16.6. Strategic overview
13.3.17. Biogen, Inc.
13.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.17.2. Business Overview
13.3.17.3. Product Portfolio
13.3.17.4. Financial Overview
13.3.17.5. SWOT Analysis
13.3.17.6. Strategic overview
13.3.18. Shire plc
13.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.18.2. Business Overview
13.3.18.3. Product Portfolio
13.3.18.4. Financial Overview
13.3.18.5. SWOT Analysis
13.3.18.6. Strategic overview
13.3.19. Amgen, Inc.
13.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.19.2. Business Overview
13.3.19.3. Product Portfolio
13.3.19.4. Financial Overview
13.3.19.5. SWOT Analysis
13.3.19.6. Strategic overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers